2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

74 239

Cited 0 times in

Cited 51 times in

Authors: J Herrstedt ; R Clark-Snow ; C H Ruhlmann ; A Molassiotis ; I Olver ; B L Rapoport ; M Aapro ; K Dennis ; P J Hesketh ; R M Navari ; L Schwartzberg ; M L Affronti ; M A Garcia-Del-Barrio ; A Chan ; L Celio ; R Chow ; M Fleury ; R J Gralla ; R Giusti ; F Jahn ; H Iihara ; E Maranzano ; V Radhakrishnan ; M Saito ; P Sayegh ; S Bosnjak ; L Zhang ; J Lee ; V Ostwal ; T Smit ; A Zilic ; K Jordan ; F Scotté

MeSH: Humans ; Nausea / chemically induced ; Nausea / prevention & control ; Radiation Oncology* ; Vomiting* / chemically induced ; Vomiting* / prevention & control

Keywords: MASCC–ESMO Clinical Practice Guideline ; chemotherapy ; nausea and vomiting ; prevention ; radiotherapy

Abstract: • Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.
• The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting.
• The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates.
• Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade).
• All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.